DNL 104

Drug Profile

DNL 104

Alternative Names: DNL104; DNLI-A-002

Latest Information Update: 27 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Harvard University
  • Developer Denali Therapeutics Inc
  • Class Neuroprotectants
  • Mechanism of Action Cell death inhibitors; Receptor-interacting protein serine-threonine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neurodegenerative disorders

Most Recent Events

  • 27 Mar 2018 Discontinued - Phase-I for Neurodegenerative disorders in Netherlands (unspecified route)
  • 25 Aug 2016 Denali Therapeutics acquires Incro Pharmaceuticals
  • 25 Aug 2016 Denali Therapeutics plans a phase-I trial for Neurodegenerative disorders in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top